Search company, investor...

Predict your next investment

Kyowa company logo
Corporation
kyowa-group.co.jp

Investments

5

About Kyowa

Kyowa (協和) is focused on cosmetics and health foods.

Headquarters Location

9F Shinjuku Sanee Building 1-22-2 West Shinjuku, Shunjuku Ward

Tokyo, 160-0023,

Japan

+81 04-5326-8001

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Kyowa News

Secondary Hyperparathyroidism Market, Epidemiology, Clinical Trials and FDA Approvals by DelveInsight | Amgen, OPKO Health, AbbVie, Shire, Roche, Sanofi, Kyowa Hakko Kirin, Astellas Pharma, Leo Pharma

Feb 19, 2024

Secondary Hyperparathyroidism Market (New York, USA) DelveInsight’s “Secondary Hyperparathyroidism Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Secondary Hyperparathyroidism, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Secondary Hyperparathyroidism market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Secondary Hyperparathyroidism market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Secondary Hyperparathyroidism treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Secondary Hyperparathyroidism market. Some facts of the Secondary Hyperparathyroidism Market Report are: According to DelveInsight, Secondary Hyperparathyroidism market size is expected to grow at a decent CAGR by 2032. Leading Secondary Hyperparathyroidism companies working in the market are Amgen Inc., OPKO Health, Inc., AbbVie Inc., Shire Plc, F. Hoffmann-La Roche AG, Sanofi S.A., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc, KAI Pharmaceuticals, Leo Pharma A/S, Shanghai Hengrui Pharmaceutical Co., Ltd, KAI Pharmaceuticals, Abbott, Sanwa Kagaku Kenkyusho Co., Deltanoid Pharmaceuticals and others. Key Secondary Hyperparathyroidism Therapies expected to launch in the market are KHK7580, Cinacalcet Hydrochloride, Etelcalcetide, ASP7991, SHR6508, Dose-adjusted SK-1403, DP001, Sensipar, Paricalcitol, Doxercalciferol (GZ427397), Sensipar, and others. Secondary Hyperparathyroidism Overview Secondary hyperparathyroidism is a medical condition that occurs as a result of chronic kidney disease (CKD) or other conditions that lead to prolonged imbalances in calcium and phosphorus levels in the body. It involves the overactivity of the parathyroid glands, which are responsible for regulating calcium and phosphorus metabolism. Secondary hyperparathyroidism primarily occurs as a compensatory response to imbalances in calcium and phosphorus metabolism, commonly associated with chronic kidney disease. In CKD, the kidneys are unable to effectively regulate calcium and phosphorus levels, resulting in low calcium and high phosphorus levels. As a result, the parathyroid glands produce excessive PTH to maintain calcium balance, leading to hyperparathyroidism. Learn more about Secondary Hyperparathyroidism treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @  https://www.delveinsight.com/sample-request/secondary-hyperparathyroidism-market Secondary Hyperparathyroidism Market The Secondary Hyperparathyroidism market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Secondary Hyperparathyroidism market trends by analyzing the impact of current Secondary Hyperparathyroidism therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Secondary Hyperparathyroidism market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Secondary Hyperparathyroidism market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Secondary Hyperparathyroidism market in 7MM is expected to witness a major change in the study period 2019-2032. Secondary Hyperparathyroidism Epidemiology The Secondary Hyperparathyroidism epidemiology section provides insights into the historical and current Secondary Hyperparathyroidism patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Secondary Hyperparathyroidism market report also provides the diagnosed patient pool, trends, and assumptions. Secondary Hyperparathyroidism Drugs Uptake This section focuses on the uptake rate of the potential Secondary Hyperparathyroidism drugs recently launched in the Secondary Hyperparathyroidism market or expected to be launched in 2019-2032. The analysis covers the Secondary Hyperparathyroidism market uptake by drugs, patient uptake by therapies, and sales of each drug. Secondary Hyperparathyroidism Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Secondary Hyperparathyroidism market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Secondary Hyperparathyroidism Pipeline Development Activities The Secondary Hyperparathyroidism report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Secondary Hyperparathyroidism key players involved in developing targeted therapeutics. Secondary Hyperparathyroidism Therapeutics Assessment Major key companies are working proactively in the Secondary Hyperparathyroidism Therapeutics market to develop novel therapies which will drive the Secondary Hyperparathyroidism treatment markets in the upcoming years are Amgen Inc., OPKO Health, Inc., AbbVie Inc., Shire Plc, F. Hoffmann-La Roche AG, Sanofi S.A., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc, KAI Pharmaceuticals, Leo Pharma A/S, Shanghai Hengrui Pharmaceutical Co., Ltd, KAI Pharmaceuticals, Abbott, Sanwa Kagaku Kenkyusho Co., Deltanoid Pharmaceuticals and others. 1. Secondary Hyperparathyroidism Patient Population 2. Secondary Hyperparathyroidism Market Size and Trends 3. Key Cross Competition in the Secondary Hyperparathyroidism Market 4. Secondary Hyperparathyroidism Market Dynamics (Key Drivers and Barriers) 5. Secondary Hyperparathyroidism Market Opportunities 6. Secondary Hyperparathyroidism Therapeutic Approaches 7. Secondary Hyperparathyroidism Pipeline Analysis 8. Secondary Hyperparathyroidism Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Secondary Hyperparathyroidism Market

Kyowa Investments

5 Investments

Kyowa has made 5 investments. Their latest investment was in EVERING as part of their Series A on May 31, 2022.

CBI Logo

Kyowa Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/31/2022

Series A

EVERING

$7.78M

Yes

2

3/1/2022

Corporate Minority

Subscribe to see more

Subscribe to see more

10

8/10/2021

Series C - II

Subscribe to see more

Subscribe to see more

10

12/27/2019

Series C

Subscribe to see more

$99M

Subscribe to see more

10

2/25/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/31/2022

3/1/2022

8/10/2021

12/27/2019

2/25/2019

Round

Series A

Corporate Minority

Series C - II

Series C

Series A

Company

EVERING

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$7.78M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

10

10

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.